U.S. markets closed
  • S&P Futures

    4,238.00
    +1.75 (+0.04%)
     
  • Dow Futures

    33,866.00
    +31.00 (+0.09%)
     
  • Nasdaq Futures

    14,273.25
    +15.00 (+0.11%)
     
  • Russell 2000 Futures

    2,294.30
    +1.80 (+0.08%)
     
  • Crude Oil

    73.08
    +0.02 (+0.03%)
     
  • Gold

    1,778.20
    +0.80 (+0.05%)
     
  • Silver

    25.83
    -0.02 (-0.09%)
     
  • EUR/USD

    1.1942
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.4720
    -0.0120 (-0.81%)
     
  • Vix

    16.66
    -1.23 (-6.88%)
     
  • GBP/USD

    1.3945
    -0.0002 (-0.01%)
     
  • USD/JPY

    110.7080
    +0.0730 (+0.07%)
     
  • BTC-USD

    32,417.65
    +984.98 (+3.13%)
     
  • CMC Crypto 200

    766.94
    -27.39 (-3.45%)
     
  • FTSE 100

    7,090.01
    +27.72 (+0.39%)
     
  • Nikkei 225

    28,884.13
    +873.20 (+3.12%)
     

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will present at the Bank of America Healthcare Conference on Thursday, May 13, 2021. The company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

Bank of America Healthcare Conference

Date:

Thursday, May 13, 2021

Time:

12:30 PM ET

Webcast:

http://www.veracast.com/webcasts/bofa/hc2021/idMy79HJ.cfm

A replay of the presentation will be available by visiting the “Events & Presentations” section of the PMV Pharmaceuticals website.

About PMV Pharma

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.

Contact

For Investors & Media:

Winston Kung
Chief Financial Officer
investors@pmvpharma.com